Our mission is to support transformational companies and drive innovation in life sciences
Mianus Capital (formerly Keylian Asset Management) was founded in 2015 in New York City with an office in Shanghai. In the early years, Mianus focused on wealth management for a group of high-net worth individuals and affluent families. Mianus made investments across real estate, education, technology, and life sciences.
Since 2019, Mianus specializes in healthcare and life sciences. We invested in a fast-growing, innovative service company, also known as a contract research organization or CRO. The CRO provides technology and service solutions for clinical trials conducted by pharmaceutical and biotech companies worldwide. This affords Mianus a strategic platform with a unique advantage for high-quality deal sourcing, as well as access to vast scientific, clinical, and commercial expertise. The CRO is also an operational resource to support venture capital and private equity investments in life sciences.
We collaborate with our strategic partner MERIT CRO, Inc. to launch our inaugural venture capital fund, Mianus Clarity Fund, which will focus on driving global innovation primarily in ophthalmology to significantly improve people’s vision and quality of life. MERIT CRO is proud to be the market leader with a premier brand and unparalleled expertise in global ophthalmology clinical trials. MERIT CRO supports the fund with access to high-quality deal flow, vast domain expertise and resource to pursue investment opportunities in the global ophthalmology market.
As a funding partner for our platform company, MERIT CRO, Inc., we raise capital to support their growth initiatives including roll-up acquisition of small to mid-sized CROs. We expect investment in a well-established company like MERIT, with robust growth potential, to deliver stable and attractive returns for our investors.